CancerNetwork®’s podcast features Jennifer Caudle, MD, as she hosts Daniel DeAngelo, MD, to discuss the role of minimal/measurable residual disease testing in the treatment of patients with MRD(+) CD19-positive B-cell precursor acute lymphoblastic leukemia.
Host Dr. Jennifer Caudle
Guest Dr. Daniel DeAngelo
This program is intended for physicians. Amgen provided funding for this podcast and compensated the presenters for participating in this program. This program is not independent medical education and is not eligible for CME credit.
When it comes to managing B-cell precursor acute lymphoblastic leukemia (ALL), there’s been growing discussion about the prognostic value of minimal/measurable residual disease (MRD). Research has found that the presence of MRD is a strong predictor of relapse, which may lead to poor patient outcomes. These findings not only support the importance of MRD testing, but treatment for those who test MRD(+).1
Join Dr. Jennifer Caudle as she hosts Dr. Daniel DeAngelo, a medical oncologist from the Dana-Farber Cancer Institute in Boston and professor of medicine at Harvard Medical School, to discuss MRD testing and using BLINCYTO® (blinatumomab) for the treatment of patients with CD19-positive B-cell precursor ALL who are MRD(+) after induction therapy.2
In this discussion, Dr. DeAngelo will review:
After listening to the discussion, visit www.blincytohcp.com to learn if BLINCYTO® may be right for your patients with MRD(+) CD19-positive B-cell precursor ALL.
ALL = acute lymphoblastic leukemia; MRD = minimal/measurable residual disease; MRD(+) = minimal/measurable residual disease positive.
BLINCYTO® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation.
BLINCYTO® is a registered trademark of Amgen Inc.
© 2021 Amgen Inc. All rights reserved. USA-103-80825